top of page
Home
Reports
Recruitment
Our Team
All Posts
TMT
Healthcare
Industrials
Financials
Consumer
Venture Capital
Growth Equity
Blackstone Life Sciences' $3.1BN sale of Anthos Therapeutics to Novartis
Novartis reacquires Anthos from Blackstone after cardiovascular drug abelacimab shows promise. A successful PE/Biopharma model emerges.
bottom of page